Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News SkyePharma: Requip XL success shows value of drug delivery technology

SkyePharma: Requip XL success shows value of drug delivery technology

17th June 2008

SkyePharma has announced that the success of Requip XL (ropinirole extended-release tablets) is evidence of the clinical value of its drug delivery technology.

The compound from GlaxoSmithKline (GSK) is the first once-daily orally-administered non-ergot dopamine agonist indicated for Parkinson’s disease.

It was recently approved by the US Food and Drug Administration in this indication and is expected to be available from the beginning of next months.

The novel tri-layer XL formulation of the drug uses patented Geomatrix technology from SkyePharma and facilitates continuous delivery of the medication over a 24-hour period to offer patients smooth blood levels of the compound.

Approval for the drug was based mainly on results from the Ease-PD adjunct study of the compound in patients with idiopathic Parkinson’s disease that was not sufficiently controlled with 1-dopa.

Frank Condella, chief executive officer of SkyePharma, expressed his pleasure with the regulatory approval of Requip XL.

“This represents yet another successful collaboration between SkyePharma and GSK and demonstrates the clinical value of our drug delivery technologies,” he said.

Following its approval, GSK noted that at present, many patients require more than one dose of multiple medications to control the symptoms of Parkinson’s disease which can prove challenging, a situation that could potentially be improved by the use of Requip XL.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.